A groundbreaking trial exploring the potential of blood tests to diagnose dementia is now underway in Imperial College Healthcare NHS Trust, marking a significant step towards improving the UK’s dementia diagnosis rate.
The pioneering study’s expansion further strengthens efforts to assess whether blood tests could provide a faster, simpler and more accessible way of diagnosing dementia.
This initiative, led by the READ-OUT research team at Dementias Platform UK (DPUK), seeks to address gaps in diagnosis and enhance early detection of the diseases that can cause dementia, ultimately improving outcomes for people living with the condition.
The READ-OUT (REAl World Dementia OUTcomes) study is part of the Blood Biomarker Challenge – a multi-million-pound initiative led by Alzheimer’s Society and Alzheimer’s Research UK, supported by funds raised by Postcode Lottery players, National Institute for Health and Care Research and Gates Ventures. It aims to explore whether a panel of blood tests can complement existing diagnostic pathways in NHS memory clinics, helping clinicians provide faster and more accurate diagnoses for people living with dementia.
The team will assess multiple new and existing blood tests, looking at a range of dementia types including Alzheimer’s disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies. The researchers will also look at whether the blood tests can help detect these diseases at various stages and if the results need to be interpreted differently in people from different ethnic backgrounds or with other health conditions such as kidney disease.
The first participants joined the study in Oxford in January 2025, marking the start of a nationwide drive to recruit over 3,100 participants from 37 DPUK sites across the UK. These sites, located in NHS memory clinics and community buses, aim to recruit participants from a diverse range of communities, ensuring the research is inclusive and reflects the wider population.
Professor Vanessa Raymont, Director of Dementias Platform UK and Associate Professor, University of Oxford, and Co-Lead of the READ-OUT study, said: “We’re in an incredibly exciting time for dementia research right now, with new drugs that can slow early Alzheimer’s disease. Although these are not yet approved for use in the NHS, we urgently need to revolutionise the way we diagnose people in this country – it will be nothing short of disastrous if people are unable to get a diagnosis early enough to benefit from the new drugs, once they do become available. In addition, many people now want and need the more accurate diagnosis blood biomarkers could provide.
“Blood biomarker tests could be the answer to this problem and the good news is that the technology already exists. What we’re missing is the proof that they really do work in a real-world setting. Our team will be looking at a range of blood tests and we are actively recruiting participants in north west London from a broad range of people including those from minority ethnic groups, the very elderly and people with other medical conditions. This will show us how the blood tests perform in different UK populations.”
This research will provide vital evidence needed to integrate blood tests into routine clinical practice in the NHS, ultimately improving diagnosis speed and accuracy, and ensuring that more people within London receive timely treatments and support.
Laura Chow, head of charities at Postcode Lottery, said: “We are thrilled to see the groundbreaking blood test trial for dementia diagnosis now expanding in London. This marks a pivotal moment in the fight against dementia and highlights the immense value of funding raised by Postcode Lottery players. Early diagnosis is crucial in improving outcomes for individuals living with dementia, and I am delighted that our players are supporting a project that has the potential to transform how the condition is detected and managed. We look forward to seeing the positive impact this innovative work could have across the UK.”
